HKSE:02637 (China)
Â
Class H
HK$
204.8
+6.5 (+3.28%)
Aug 14
Business Description
Fujian Haixi Pharmaceuticals Co Ltd
ISIN : CNE100007515
Share Class Description:
HKSE:02637: Class HTotal Employee Number:
200Compare
Compare
Traded in other countries / regions
02637.Hong Kong Index Membership
Hong Kong Stock Connect IPO Date
2025-10-20Description
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.08 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.52 | |||||
Interest Coverage | 34.42 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 36.37 | |||||
Beneish M-Score | -2.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 45.3 | |||||
3-Year EBITDA Growth Rate | 32.8 | |||||
3-Year EPS without NRI Growth Rate | 43.8 | |||||
3-Year FCF Growth Rate | 33.9 | |||||
3-Year Book Growth Rate | 76.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.88 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.53 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.8 | |||||
9-Day RSI | 65.35 | |||||
14-Day RSI | 59.73 | |||||
3-1 Month Momentum % | -14.85 | |||||
6-1 Month Momentum % | 44.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.31 | |||||
Quick Ratio | 6.06 | |||||
Cash Ratio | 5.83 | |||||
Days Inventory | 170.14 | |||||
Days Sales Outstanding | 27.1 | |||||
Days Payable | 58.66 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.38 | |||||
Operating Margin % | 33.9 | |||||
Net Margin % | 30.4 | |||||
EBITDA Margin % | 36.32 | |||||
FCF Margin % | 19.74 | |||||
OCF Margin % | 27.45 | |||||
ROE % | 16.73 | |||||
ROA % | 13.74 | |||||
ROIC % | 37.98 | |||||
3-Year ROIIC % | 26.72 | |||||
ROC (Joel Greenblatt) % | 63.57 | |||||
ROCE % | 18.76 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 72.7 | |||||
Forward PE Ratio | 66.06 | |||||
PE Ratio without NRI | 70.33 | |||||
PS Ratio | 22.13 | |||||
PB Ratio | 9.16 | |||||
Price-to-Tangible-Book | 9.16 | |||||
Price-to-Free-Cash-Flow | 112.1 | |||||
Price-to-Operating-Cash-Flow | 80.6 | |||||
EV-to-EBIT | 65.29 | |||||
EV-to-Forward-EBIT | 51.51 | |||||
EV-to-EBITDA | 62.9 | |||||
EV-to-Revenue | 22.85 | |||||
EV-to-Forward-Revenue | 18.29 | |||||
EV-to-FCF | 115.74 | |||||
Price-to-Graham-Number | 5.35 | |||||
| Price-to-Net-Current-Asset-Value | 12.29 | |||||
| Price-to-Net-Cash | 13.54 | |||||
Earnings Yield (Greenblatt) % | 1.53 | |||||
FCF Yield % | 0.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fujian Haixi Pharmaceuticals Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 643.346 | ||
| EPS (TTM) (HK$) | 2.817 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 59.73 | ||
| 14-Day ATR (HK$) | 12.389646 | ||
| 20-Day SMA (HK$) | 186.655 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (HK$) | 124 - 302.4 | ||
| Shares Outstanding (Mil) | 78.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fujian Haixi Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fujian Haixi Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fujian Haixi Pharmaceuticals Co Ltd Frequently Asked Questions
What is Fujian Haixi Pharmaceuticals Co Ltd(HKSE:02637)'s stock price today?
The current price of HKSE:02637 is HK$204.80. The 52 week high of HKSE:02637 is HK$302.40 and 52 week low is HK$124.00.
When is next earnings date of Fujian Haixi Pharmaceuticals Co Ltd(HKSE:02637)?
The next earnings date of Fujian Haixi Pharmaceuticals Co Ltd(HKSE:02637) is .
Does Fujian Haixi Pharmaceuticals Co Ltd(HKSE:02637) pay dividends? If so, how much?
Fujian Haixi Pharmaceuticals Co Ltd(HKSE:02637) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Fujian Haixi Pharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers